Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report
| Autor: | Muhammet Ali Kaplan, Abdullah Altintas, Orhan Ayyildiz, İlhan Kılınç, Timucin Cil |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Male Cancer Research Antineoplastic Agents Blastic Phase Dexamethasone Piperazines Central Nervous System Neoplasms Myelogenous hemic and lymphatic diseases Leukemia Myelogenous Chronic BCR-ABL Positive Antineoplastic Combined Chemotherapy Protocols Medicine Humans Sarcoma Myeloid neoplasms business.industry breakpoint cluster region Cytarabine Myeloid leukemia Imatinib Protein-Tyrosine Kinases medicine.disease Magnetic Resonance Imaging Leukemia Imatinib mesylate Methotrexate Pyrimidines Treatment Outcome Neurology Oncology Blood-Brain Barrier Benzamides Cancer research Imatinib Mesylate Neurology (clinical) business Blast Crisis medicine.drug |
| Zdroj: | Journal of neuro-oncology. 84(1) |
| ISSN: | 0167-594X |
| Popis: | Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by a reciprocal translocation between chromosomes 9 and 22. Imatinib mesylate is a potent and selective inhibitory of the BCR/ABL tyrosine kinase. Imatinib is a first choice of treatment of chronic phase CML. It has also shown activity in patients with CML in accelerated or blastic phases. However, the penetration of the drug and its active metabolites into the central nervous system (CNS) is poor. Therefore, the CNS is sanctuary site for malignant cells in patients treated with imatinib. Herein, we report a patient with CML in accelerated phase that developed central nervous system disease while on imatinib mesylate therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink